Science Explorer Back to mapMap
Discussion
Institution · Astellas Pharma (Netherlands)

Most cited papers from Astellas Pharma (Netherlands)

Astellas Pharma (Netherlands)

What are the most cited papers from Astellas Pharma (Netherlands)?

The most cited paper from Astellas Pharma (Netherlands) is "ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer" (Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak et al., 2019), with 1,239 citations. Next come "Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial" (429) and "Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study" (426).

Showing 50 of 61 papers. Every paper with more than 91 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak et al. · Journal of Clinical Oncology Open access 22 Jul 2019 1,239
2 Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology 6 Nov 2012 429
3 Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study Tomasz M. Beer et al. · European Urology Open access 29 Jul 2016 426
4 Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access 10 Jan 2018 390
5 Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity Dan H. Barouch, Maria Grazia Pau, Jerome H. H. V. Custers et al. · The Journal of Immunology Open access May 2004 388
6 Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder Christopher Reginald Chapple, Steven A. Kaplan, David Mitcheson et al. · European Urology 6 Nov 2012 361
7 Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology 23 May 2013 317
8 Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study Neal D. Shore, Simon Chowdhury, Arnauld A. Villers et al. · The Lancet Oncology 13 Jan 2016 289
9 Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison Khaled Maman, Samuel Aballéa, Jameel Nazir et al. · European Urology Review 21 Nov 2013 258
10 A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder Sender Herschorn, Jack Barkin, David Manuel Castro-Diaz et al. · Urology 13 Jun 2013 249
11 Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony) Paul Abrams, Con J. Kelleher, David R. Staskin et al. · European Urology 19 Feb 2014 247
12 Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature Cathelijne Alleman, Kirsten Y Westerhout, Marja Hensen et al. · Diabetes Research and Clinical Practice Open access 5 May 2015 234
13 Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis Con J. Kelleher, Zalmaï Hakimi, Richard M. Zur et al. · European Urology ReviewOpen access 23 Apr 2018 228
14 The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults Brian Abel et al. · American Journal of Respiratory and Critical Care Medicine Open access 18 Feb 2010 227
15 Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies Victor W. Νitti, V. Khullar, Philip E.V. van Kerrebroeck et al. · International Journal of Clinical Practice Open access 21 May 2013 213
16 Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice Christopher Reginald Chapple, Jameel Nazir, Zalmaï Hakimi et al. · European Urology Open access 11 Feb 2017 209
17 Extensions to the Visual Predictive Check to facilitate model performance evaluation Teun M. Post, Jan I. Freijer, Bart A. Ploeger et al. · Journal of Pharmacokinetics and Pharmacodynamics Open access 15 Jan 2008 206
18 Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi et al. · Journal of the American Society of Nephrology Open access 3 Jun 2020 205
19 SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology Open access 31 Jan 2014 198
20 Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial Yohann Loriot, Kurt Miller, Cora Nanette Sternberg et al. · The Lancet Oncology 16 Apr 2015 192
21 Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE) Marcus John Drake, Christopher Reginald Chapple, Adil Esen et al. · European Urology Open access 8 Mar 2016 186
22 RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Philippe Gabríel Steg, Shamir R. Mehta, J. Wouter Jukema et al. · European Heart Journal Open access 30 Aug 2011 185
23 Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study David Martin Simpson, Jessica Robinson‐Papp, Joanna T Van et al. · Journal of Pain Open access 16 Oct 2016 180
24 Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( SYNERGY study) Sender Herschorn, Christopher Reginald Chapple, Paul Abrams et al. · British Journal of Urology Open access 18 Apr 2017 176
25 Signs and Symptoms of Detrusor Underactivity: An Analysis of Clinical Presentation and Urodynamic Tests From a Large Group of Patients Undergoing Pressure Flow Studies Andrew Gammie, Mathilde Kaper, Caroline A. Dorrepaal et al. · European Urology 29 Aug 2015 169
26 Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial Andrew J. Armstrong, Ping Lin, Bertrand F. TOMBAL et al. · European Urology Open access 9 Jun 2020 168
27 Pharmacokinetic Drug Interaction Studies with Enzalutamide Jacqueline A. Gibbons, Michiel S. de Vries, Walter J. J. Krauwinkel et al. · Clinical Pharmacokinetics Open access 30 Apr 2015 161
28 Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector Stefan Kostense, Wouter Koudstaal, Mieke Sprangers et al. · AIDS May 2004 155
29 National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Symptom Evaluation in Multinational Cohorts of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome Florian Wagenlehner, J. W. Olivier van Till, Vittorio Magri et al. · European Urology 2 Nov 2012 154
30 Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study Marek Malík, E. Marcel van Gelderen, J H Lee et al. · Clinical Pharmacology & Therapeutics 14 Nov 2012 152
31 Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) Jonathan Barratt, Branislav Andrić, Avtandil Tataradze et al. · Nephrology Dialysis Transplantation Open access Jun 2021 150
32 Clinical Pharmacokinetic Studies of Enzalutamide Jacqueline A. Gibbons, Taoufik Ouatas, Walter J. J. Krauwinkel et al. · Clinical Pharmacokinetics Open access 27 Apr 2015 144
33 Randomised, Multicentre, Placebo-controlled, Double-blind Crossover Study Investigating the Effect of Solifenacin and Oxybutynin in Elderly People with Mild Cognitive Impairment: The SENIOR Study Adrian Wagg, Mark C Dale, Reiner Tretter et al. · European Urology 11 Jan 2013 138
34 A phase II dose-ranging study of mirabegron in patients with overactive bladder On behalf of the Dragon Investigator Group, Christopher Reginald Chapple, Vladimír Dvořák et al. · International Urogynecology Journal Open access 7 Mar 2013 136
35 The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients Priyanka Priyanka, Alexander Zarbock, Junichi Izawa et al. · Journal of Thoracic and Cardiovascular Surgery Open access 8 Jan 2020 135
36 Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial Linda Cardozo, Elke E. Heßdörfer, Rodolfo Milani et al. · British Journal of Urology Open access 6 Oct 2008 132
37 Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review Gillian Yeowell, Philip Smith, Jameel Nazir et al. · BMJ Open ReviewOpen access Nov 2018 129
38 Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Journal of Pharmacy and Pharmacology 18 Feb 2014 126
39 Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS) Evgeny V. Shutov, Władysław Sułowicz, Ciro Esposito et al. · Nephrology Dialysis Transplantation Open access 24 Feb 2021 124
40 Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe Johann Sebastian De Bono, Simon Chowdhury, Susan Feyerabend et al. · European Urology Open access 23 Aug 2017 120
41 Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities Jessica Lim, Rosalind J. Walley, Jiacheng Yuan et al. · Therapeutic Innovation & Regulatory Science Open access 18 Jun 2018 119
42 Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL Julie N. Graff, G. Baciarello, Andrew J. Armstrong et al. · Annals of Oncology Open access 18 Nov 2015 118
43 Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis Floortje E. van Nooten, M. Treur, Krystallia Pantiri et al. · Clinical Therapeutics ReviewOpen access 30 Mar 2017 117
44 Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study John P.H. Wilding, Ele Ferrannini, Vivian Andrew Fonseca et al. · Diabetes Obesity and Metabolism 19 Nov 2012 117
45 Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II) Christian Gratzke, Rob van Maanen, Christopher Reginald Chapple et al. · European Urology Open access Jun 2018 112
46 Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES) Botond Szabolcs Csiky, Michael Schömig, Ciro Esposito et al. · Advances in Therapy Open access 19 Sep 2021 111
47 Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Naunyn-Schmiedeberg s Archives of Pharmacology 3 Dec 2011 110
48 Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study Aaron I. Vinik, Serge Perrot, Etta Johanna Vinik et al. · BMC Neurology Open access Dec 2016 108
49 A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery Bengt I. Eriksson, Alexander G.G. Turpie, Michael Rud Lassen et al. · Journal of Thrombosis and Haemostasis Open access 23 Jul 2007 108
50 Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain Maija L. Haanpää, G. Cruccu, Turo J Nurmikko et al. · European Journal of Pain Open access 19 Nov 2015 107

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.